Сахарный диабет 2 типа и неалкогольная жировая болезнь печени: практические рекомендации для эндокринологов


А.С. Аметов

Сахарный диабет 2 типа (СД2) в клинической практике часто сочетается с неалкогольной жировой болезнью печени (НАЖБП), которая включает несколько клинико-морфологических форм и развивается у пациентов, не злоупотребляющих алкоголем. Сочетание СД2 и НАЖБП связано не только с высоким риском развития цирроза печени и гепатоцеллюлярной карциномы у данной категории больных. Наличие НАЖБП у пациентов с СД2 является также предиктором высокого сердечно-сосудистого риска и повышенной смертности. Несмотря на полученные данные о прогрессирующем характере течения НАЖБП у пациентов с СД2, до сих пор остается неясным вопрос о лечении НАЖБП у больных СД2.

Литература


1. Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113–19.
2. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7(8):456–65.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142 (7):1592–609.4. Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221–31.
5. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hithertounnamed disease. Mayo Clin Proc 1980;55:434–38.
6. de Marco R. et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756–61.
7. Targher G. et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541–46.
8. Schuppan D, Gorrell MD, Klein T, et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010;30(6):795–808.
9. Liagnpunsakul S, Chalasani N. What do we recommend our patients with NAFLD about alcohol consumption? Am J Gastroenterol 2012l;107(7):976–78.
10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol 2003;98:960–7.
11. Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol 2007;102: 399–408.
12. Machado M., Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600–6.
13. Marchesini G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23.
14. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106–10.
15. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Ann 1989;24:275–302.
16. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262–65.
17. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and
composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006;29:1845–50.
18. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285,E906–E16.
19. Banerji M.A, et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995;19:846–50.
20. Targher G, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with
non-alcoholic fatty liver disease. Diabet Med 2006;23:403–9.
21. Targher G, et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers
of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.
Diabet Med 2005;22:1354–58.
22. Targher G, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006;29:55–60.
23. Lautamäki R, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction
in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006;291:E282–E90.
24. Day CP, James OF. Steatohepatitis: a tale of two ‘‘hits’’? Gastroenterology 1998;114:842–45.
25. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899–905.
26. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest
2004;114:147–52.
27. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis.
Hepatology 2002;35:898–904.
28. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1705–25.
29. Fracanzani AL, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792–98.
30. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis 2012;16(3):567–85.
31. Palmentieri B. et al. The role of bright liver echo pattern on ultrasound B-mode examination in
the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485–9.
32. Mottin CC, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese
patients. Obes Surg 2004;14:635–7.
33. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–74.
34. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–62.
35. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology
2000;118(6):1117–23.
36. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1): 91–100.
37. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84(5):1513–17.
38. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45(4):846–54.
39. Harrison SA, Oliver D, Arnold HL, et al.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441–47.
40. Miyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008;28(4):519–24.
41. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44(1):27–33.
42. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive
biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50(4):1072–78.
43. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11(2):255–29.
44. Santos VN, Leite-Mor MM, Kondo M, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005;38(5): 747–53.
45. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-
FibroSURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.
46. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47(2):455–60.
47. Nobili V, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric nonalcoholic
fatty liver disease. Gastroenterology 2009;136(1):160–57.
48. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127(6):1704–13.
49. Tamura, Y. et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191–96.
50. Sjästräm, L, et al. Effects of bariatric surger on mortality in Swedish obese subjects. N Engl J
Med 2007;357:741–52.
51. Chavez-Tapia NC, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD007340. doi:10.1002/14651858. CD007340. pub2,
2010.
52. Musso G, Gambino R, Cassader M, et al. A metaanalysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79–104.
53. Selvin E, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic
review. Arch Intern Med 2008;168:2070–80.
54. Aithal GP, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with
nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176–84.
55. Belfort R, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
N Engl J Med 2006;355:2297–307.
56. Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J
Med 2010;362:1675–85.
57. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history
of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment
Pharmacol Ther 2011;34:274–85.
58. Lincoff A, Wolski K, Nicholls S, et al. Pioglitazone and risk of cardiovascular events in patients with
type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007;298:1180–88.
59. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation
may increase all-cause mortality. Ann Intern Med 2005;142:37–46.
60. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis JAMA 2007;297(8):842–57. Review. Erratum in: JAMA 2008;299(7):765–66.
61. Klein EA, Thompson IM, Tangen CM, et al.Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011;306:1549–56.
62. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287–92.
63. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62–5.
64. Chalasani N. Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005;41:690–5.
65. Lewis JH, Mortensen ME, Zweig S, et al. Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, doubleblind, placebocontrolled, multicenter trial.
Hepatology 2007;46(5):1453–63.
66. Horlander JC, Kwo PY, Cummings OW, et al. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120(Suppl.):2767.
67. Gomer-Dominguez E, Gisbert JP, Moreno-Monteagudo A, et al. A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643–47.
68. Antonopoulos S, Mikros S, Mylonopoulos M, et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184:233–34.
69. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic
fatty liver disease: The St. Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2011;106:71–7.
70. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-й выпуск //Сахарный диабет 2011. № 3 (приложение).
71. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes
in the saxagliptin drug developmentprogram for Type 2 diabetes. Postgrad Med2010;122:16–27.
72. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics
of saxagliptin. Clin Pharmacokinet 2011;50(4):253–65.
73. Инструкция по медицинскому применению лекарственного препарата Онглиза (таблетки, покрытые оболочкой, 2,5 мг, 5 мг). Регистрационное удостоверение ЛСР 08697/10 (изменение №1) от 30.03.2012.


Похожие статьи


Бионика Медиа